Newer DES Show Superior 10-year Outcome Irrespective of Polymer Type
A 66-year-old man presents to the emergency department with a 2-day history of intermittent and exertional substernal chest pain radiating to the left arm. His symptoms have not improved with over-the-counter pain killers and antacids. He has a history of hypertension and hyperlipidemia and smoked a pack of cigarette a day for the past 30 years. He takes amlodipine 10 mg once daily, lisinopril 20 mg once daily, and rosuvastatin 10 mg once daily.
On examination, his temperature is 97.4 degrees F, heart rate is 88 bpm, blood pressure is 128/74 mmHg, respiratory rate is 14, oxygen saturation is 86% on room air, and body mass index is 32 kg/m2. The remainder of his exam is unremarkable. He has no murmurs on auscultation. Electrocardiography is normal. Echocardiography demonstrates normal left ventricular ejection fraction with hypokinesis of the inferolateral myocardium. His troponin-I levels return back elevated at 4.2 ng/ml. Cardiac catheterization revealed severe 90% discrete obstruction of the mid-segment of the right coronary artery with mild disease in the left anterior descending artery and the left circumflex artery. A 3.5 mm x 12 mm permanent polymer-based everolimus-eluting stent was deployed in the right coronary artery with good angiographic result.
Which of the following statements is NOT true regarding newer-generation drug-eluting stents (DES)?